Targeted Protein Degradation (TPD) Summit 2019

2nd Targeted Protein Degradation (TPD) Summit is organized by Hanson Wade and will be held from Oct 22 - 24, 2019 at Hilton Boston Logan Airport, Boston, Massachusetts, United States of America.

Pre-conference Workshop Day: Oct 22, 2019
Main Conference: Oct 23 - 24, 2019

Description:
The 2nd Targeted Protein Degradation (TPD) 2019 is a specifically dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to capitalize on the emerging therapeutic class of protein degradation.

As the drug discovery opportunity promised within the proteome becomes a reality and previously "undruggable" targets are reached, the 2nd TPD Summit returns for 2019. 

This premier event exists not only to drive forward the translation of first generation of PROTACS and molecular glues into the clinic, but to stimulate the discussion of next generation protein degraders that harness different modalities, target highly desirable targets and capitalize on degradation pathways, beyond the ubiquitin proteasome system.

Join world-Class Experts of Protein Degradation at the 2nd TPD to Discuss:
• Identification & validation of novel targets suitable for PROTAC & molecular glue development
• New insights into mechanisms of action and identification of novel ligases beyond E3
• Going beyond UPS by landscaping autophagy &lysosomal pathway as a platform of protein degradation therapeutics
• Degrading “undruggable” proteins with PROTACS & molecular-glues
• Overcoming chemistry challenges and optimizing drug-like properties of PROTACS & molecular glues for highly potent & selective protein degradation induction
• Preclinical understanding of substrates and downstream biology as key drivers of future clinical development
• Successful translation of PROTACS & molecular glues from the laboratory to the clinic with insights from the latest data-driven preclinical and clinical case studies
• Early clinical development considerations including rational selection of dose/schedule, patient populations, tumor types for different therapeutic window and novel clinical opportunities

Time: 8:30 am to 6:00 pm